Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 6,000 shares, a growth of 1,400.0% from the June 15th total of 400 shares. Based on an average daily trading volume, of 173,400 shares, the short-interest ratio is presently 0.0 days.

Oncotelic Therapeutics Stock Performance

Shares of OTLC stock remained flat at $0.03 during trading hours on Friday. 152,856 shares of the company’s stock traded hands, compared to its average volume of 69,679. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.01 and a current ratio of 0.01. Oncotelic Therapeutics has a 52-week low of $0.02 and a 52-week high of $0.05. The stock has a 50-day simple moving average of $0.04 and a 200 day simple moving average of $0.04.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.